Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NCT04134260
Recruiting
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechani... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Cancer Center at Saint Joseph's, Phoenix, Arizona +337 locations
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
NCT04174742
Recruiting
The overall purpose of this study is to investigate whether younger subjects report pain with pegfilgrastim (or biosimilar substitution) more often and/or at higher levels (greater intensity) than older subjects.This study will be carried out throughout the course of your chemotherapy treatment, which will be prescribed by your study doctor. Participation in this study will not affect your cancer treatment.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina +1 locations
Conditions: Breast, Breast Cancer
Register for Updates
Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
NCT04337580
Recruiting
The purpose of this research study is to find out what effects (good and bad) omeprazole and cabazitaxel, or omeprazole and docetaxel, has on participants and their condition. Investigators believe omeprazole may help the other medications work.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: W.G. Bill Hefner VA Medical Center, Salisbury, North Carolina +1 locations
Conditions: Prostate Cancer, Refractory Cancer, Castration Resistant Prostatic Cancer
Register for Updates
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
NCT04342429
Recruiting
To assess the safety and efficacy of intensity-modulated proton therapy (IMPT) for small cell lung cancer (SCLC)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Winship Cancer Institute, Atlanta, Georgia
Conditions: Small-cell Lung Cancer
Register for Updates
Everyday Memory Impairment in PD-related Cognitive Decline
NCT04474379
Recruiting
The investigators will aim enroll participants into our study within 3-6 months after their parent study visit so the investigators can utilize some key data points (e.g. PD-MCI diagnosis, rs-fcMRI data) from that study. PD participants will participate in a single-blind RCT with two treatment arms: process training and strategy training (Fig 4). They will complete pre-training assessment (Pre), be randomized to treatment arm (1:1 ratio stratified by sex), and then complete 8 training sessions o... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/14/2025
Locations: Washington University School of Medicine, St. Louis, Missouri
Conditions: Parkinson Disease, Mild Cognitive Impairment
Register for Updates
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717
Recruiting
This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiatio... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska +598 locations
Conditions: Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
Register for Updates
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT04553770
Recruiting
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: St. Joseph Heritage Healthcare, Fullerton, California +8 locations
Conditions: Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
Register for Updates
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
NCT04563520
Recruiting
The purpose of the aPCC-emicizumab safety study is to investigate the hemostatic efficacy as measured by thrombin generation, of a low personalized dose of aPCC (FEIBA) in children and adults with hemophilia A and inhibitors on emicizumab prophylaxis.
Gender:
ALL
Ages:
6 years and above
Trial Updated:
07/14/2025
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia +1 locations
Conditions: Hemophilia A
Register for Updates
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
NCT04640142
Recruiting
Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases
Gender:
ALL
Ages:
Between 2 years and 75 years
Trial Updated:
07/14/2025
Locations: Octapharma Research Site, Irvine, California +25 locations
Conditions: Primary Immune Deficiency
Register for Updates
Comprehensive Esophageal Diagnostics Study
NCT04641702
Recruiting
The prospective clinical trial will study muscle fibrosis in relation to lower esophageal sphincter (LES) measurements on Functional Lumen Imaging Probe (FLIP) Topography (the novel technology that utilizes impedance planimetry) after pharmacologic challenge. A better understanding of achalasia will allow intervention at an earlier stage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Emory University Hospital, Atlanta, Georgia +1 locations
Conditions: Achalasia
Register for Updates
Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
NCT04683653
Recruiting
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to en... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Winship Cancer Institute, Emory University, Atlanta, Georgia +4 locations
Conditions: Endometrial Cancer
Register for Updates
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
NCT04704323
Recruiting
Introduction of immuno-chemotherapy in the treatment options of CLL and SLL changed the treatment paradigm of these diseases. Presently, first-line therapies for CLL/SLL include targeted therapies (e.g. ibrutinib, acalabrutinib) or combined immuno-chemotherapy regimens (e.g., fludarabine, cyclophosphamide, and rituximab for patients aged \<65 years without del17p/TP53 mutations or bendamustine and rituximab for patients ≥65 years who have additional comorbidities). Despite the gradual introduct... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/14/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +3 locations
Conditions: Lymphocytic Leukemia, Chronic, SLL
Register for Updates